Printer Friendly

Panther Biotechnology starts formal drug development process for Transferrin Doxorubicin.

M2 PHARMA-July 18, 2016-Panther Biotechnology starts formal drug development process for Transferrin Doxorubicin

(C)2016 M2 COMMUNICATIONS

Panther Biotechnology, a company focused on the acquisition and development of small molecule therapeutics for the treatment of Leukaemia, Lymphoma and Myeloma, has started the formal drug development process for its lead compound, Transferrin Doxorubicin, it was reported on Friday.

Panther entered into a definitive agreement with privately held Faulk Pharmaceuticals Inc in April 2015, to acquire Faulk's pharmaceutical technology assets which included TRF-DOX.

The deal provided the company with a proprietary, multi-nationally patent protected, ligand-drug conjugate technology platform and a range of drug product candidates that address unmet medical needs in oncology, autoimmune, antiviral and other disease indications. TRF-DOX is a combination of the iron-binding glycoprotein, transferrin, and Doxorubicin resulting in targeted delivery to tumours with the reduction of serious side effects.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 18, 2016
Words:151
Previous Article:Avacta Group collaborates with Glythera.
Next Article:Provectus Biopharmaceuticals establishes Provectus Australia.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters